clinical trial · NCT06260163
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development, LLC·phase3·active not recruiting·n = 112
Colitis, UlcerativeGuselkumab SubcutaneousGuselkumab Intravenous
brief summary
The purpose of this study is to evaluate the efficacy of guselkumab in pediatric participants with moderately to severely active ulcerative colitis at the end of maintenance therapy among participants who were induction responders.
started
Jan 19, 2024
primary completion
Feb 10, 2027
completion
Apr 28, 2027
last updated
Aug 28, 2026
official title
A Phase 3 Randomized, Open-label Induction, Double-blind Maintenance, Parallel-group, Multicenter Protocol to Evaluate the Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol